Purchase Order 75F40119P10376
Award Date 7/11/19
Potential Completion Date 7/11/24
Potential Value $65K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Princeton, NJ, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $91,396 firm fixed-price purchase order issued by the Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (De), for the ratification of Phoenix Quantum licenses in fiscal year 2017. Certara is a technology-enabled drug development and drug safety consultancy that specializes in biosimulation and has received multiple federal contracts from the Department of Health and Human Services, including the FDA, National Institutes of Health, and Centers for...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Pharsight Corporation, a subsidiary of Certara USA Inc. The contract, valued at $153,470.00, is for the provision of the "PHOENIX QUANTUM SOFTWARE BUNDLE" and is a total small business set-aside. The contract has a completion date of July 21, 2017. Certara USA Inc. is a leading global technology-enabled drug development and drug safety consultancy, specializing in biosimulation...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Certara USA Inc., a leading provider of biosimulation software and consulting services. The contract, valued at $16,441.10, is for the procurement of software licenses for Certara's proprietary modeling and simulation tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers to conduct...
- The Department of Health and Human Services' National Institutes of Health has awarded a firm fixed-price purchase order to Certara USA Inc., a leading global drug development and drug safety consultancy, for the provision of Phoenix WinNonlin software licenses. The $12,266.00 contract will enable federal scientists and reviewers to conduct clinical pharmacology, pharmacometric, and regulatory review analyses on data submitted by industry sponsors. Certara has received numerous prime contracts...
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Purchase Order contract to Certara USA Inc. for the procurement of the Phoenix WinNonlin software. The contract has a potential value of $19,950.00 and a completion date of May 31, 2025. This contract supports federal scientists and reviewers in conducting clinical pharmacology, pharmacometric, and regulatory review analyses on...
- The Food and Drug Administration awarded a firm fixed-price purchase order to Certara UK LIMITED (doing business as Certara) on September 6, 2023, for SIMCYP software licenses with a ceiling value of $815,948. The contract will be performed in Great Britain, United Kingdom, and is scheduled for ultimate completion by September 20, 2028. No set-aside designation was applied to this award. Certara provides physiologically-based pharmacokinetic (PBPK) modeling software that simulates drug...
- This is a firm-fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Certara USA Inc. for the annual provision of the Phoenix WinNonlin software. The $17,556.00 contract has a period of performance ending on July 22, 2025 and is not designated as a set-aside award. Certara USA Inc. is a leading global technology-enabled drug development and drug safety...
- The federal contract award, valued at $10,743.00, was issued by the National Cancer Institute (NCI) to Certara USA Inc., a leading global technology-enabled drug development and drug safety consultancy, for the procurement of software licenses. The contract is a firm-fixed price purchase order with no set-aside designation and an ultimate completion date of August 13, 2025. Certara USA Inc. has received numerous prime contract awards from the NCI, Food and Drug Administration (FDA), and National...
- The Department of Health and Human Services' Food and Drug Administration awarded a $43,243.20 firm fixed price purchase order to Certara USA Inc. for SEND EXPLORER licenses. The place of performance is Silver Spring, Maryland. The one-year contract runs from September 12, 2023 through September 14, 2024. Certara USA Inc. will provide the FDA with software licenses to support the agency's regulatory science and public health protection missions. No subcontractors or set asides were identified....
- The U.S. Food and Drug Administration (FDA) awarded a $144,000.00 firm-fixed-price purchase order contract to Certara UK LIMITED, doing business as Certara, for the purchase of SIMCYP software. SIMCYP is a physiologically-based pharmacokinetic (PBPK) modeling software used to simulate drug absorption, distribution, metabolism, and excretion processes, which is crucial for optimizing drug development and facilitating regulatory reviews. This contract is not set aside for any specific business...